IGC Stock Summary and Trading Ideas (Igc Pharma | AMEX:IGC)

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Igc Pharma trades on the AMEX stock market under the symbol IGC.

As of April 23, 2024, IGC stock price climbed to $0.46 with 488,156 million shares trading.

IGC has a beta of 0.53, meaning it tends to be less sensitive to market movements. IGC has a correlation of 0.01 to the broad based SPY ETF.

IGC has a market cap of $30.51 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, IGC stock traded as high as $4.65 and as low as $.25.

The top ETF exchange traded funds that IGC belongs to (by Net Assets): VXF.

IGC has outperformed the market in the last year with a return of +26.8%, while the SPY ETF gained +24.3%. In the last 3 month period, IGC beat the market returning +70.7%, while SPY returned +4.9%. However, in the most recent 2 weeks IGC has underperformed the stock market by returning -26.4%, while SPY returned -2.5%.

IGC support price is $.39 and resistance is $.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IGC stock will trade within this expected range on the day.